*Vietnam Authority of HIV/AIDS Control, Ministry of Health, Hanoi, Vietnam; †World Health Organization Vietnam Country Office, Hanoi, Vietnam; ‡Health Policy Unit, Ministry of Health, Hanoi, Vietnam; §Lee Kuan Yew School of Public Policy, National University of Singapore, Singapore; and ‖National Hospital for Tropical Diseases, Hanoi, Vietnam.
J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e1-7. doi: 10.1097/QAI.0b013e3182a17d15.
Vietnam achieved rapid scale-up of antiretroviral therapy (ART), although external funds are declining sharply. To achieve and sustain universal access to HIV services, evidence-based planning is essential. To date, there had been limited HIV treatment and care cost data available in Vietnam.
Cost data of outpatient and inpatient HIV care were extracted at 21 sentinel facilities (17 adult and 4 pediatric) that epitomize the national program. Step-down costing for administration costs and bottom-up resource costing for drugs, diagnostics, and labor were used. Records of 1401 adults and 527 pediatric patients were reviewed.
Median outpatient care costs per patient-year for pre-ART, first year ART, later year ART, and second-line ART were US $100, US $316, US $303, and US $1557 for adults; and US $171, US $387, US $320, and US $1069 for children, respectively. Median inpatient care cost per episode was US $162 for adults and US $142 for children. Non-antiretroviral (ARV) costs in adults at stand-alone facilities were 44% (first year ART) and 24% (later year ART) higher than those at integrated facilities. Adults who started ART with CD4 count ≤100 cells per cubic millimeter had 47% higher non-ARV costs in the first year ART than those with CD4 count >100 cells per cubic millimeter. Adult ARV drug costs at government sites were from 66% to 85% higher than those at donor-supported sites in the first year ART.
The study found that HIV treatment and care costs in Vietnam are economical, yet there is potential to further promote efficiency through strengthening competitive procurement, integrating HIV services, and promoting earlier ART initiation.
越南迅速扩大了抗逆转录病毒疗法(ART)的规模,尽管外部资金急剧减少。为了实现并维持普及艾滋病毒服务,必须进行基于证据的规划。迄今为止,越南提供的艾滋病毒治疗和护理费用数据有限。
在 21 个监测点(17 个成人和 4 个儿科)提取了门诊和住院艾滋病毒护理的成本数据,这些监测点代表了国家方案。采用逐步降低管理成本和自下而上核算药物、诊断和劳动力资源成本的方法。审查了 1401 名成年患者和 527 名儿科患者的记录。
成人患者接受 ART 前、第一年 ART、第二年 ART 和二线 ART 的门诊护理患者年人均费用中位数分别为 100 美元、316 美元、303 美元和 1557 美元;儿童患者分别为 171 美元、387 美元、320 美元和 1069 美元。成人患者每次住院治疗的费用中位数为 162 美元,儿童患者为 142 美元。独立机构的非抗逆转录病毒(ARV)费用在第一年 ART 中比综合机构高 44%(第一年 ART),在第二年 ART 中高 24%。CD4 计数≤100 个细胞/立方毫米开始接受 ART 的成人患者在第一年 ART 中非 ARV 费用比 CD4 计数>100 个细胞/立方毫米的患者高 47%。在第一年 ART 中,政府机构的成人抗逆转录病毒药物费用比捐赠者支持的机构高 66%至 85%。
研究发现,越南的艾滋病毒治疗和护理费用是经济的,但通过加强竞争性采购、整合艾滋病毒服务和促进早期开始 ART,可以进一步提高效率。